<DOC>
	<DOCNO>NCT02830048</DOCNO>
	<brief_summary>Diabetes chronic condition affect 1 16 people UK , lead difficulty control blood sugar level . This due imbalance two main hormone : insulin , lower blood sugar , glucagon , cause rise . Most current anti-diabetic medication work improve insulin level , however research shift good understand glucagon level play key role disease . Glibenclamide type anti-diabetic medication ( sulfonylurea ) commonly use increase amount insulin release pancreatic beta-cells . Studies mice human cell donor type 2 diabetes show sulfonylurea also improve glucagon level use small dos work different cell pancreas ( alpha-cells ) . The aim study find whether low dos glibenclamide improve glucagon level patient type 2 diabetes , whether future could use well control high blood sugar level , without risk cause low blood sugar . Participants type 2 diabetes diet-controlled metformin give liquid contain low dose glibenclamide . They need attend OCDEM Clinical Research Unit Churchill Hospital , Oxford , early morning blood test every 3-4 day period 3 week . A continuous glucose monitor also fit time . This study fund NIHR OxBRC .</brief_summary>
	<brief_title>Low dosE GlibENclamide Diabetes Part A</brief_title>
	<detailed_description>This investigator-initiated clinical trial single-centre , open-label , non-randomised , dose-finding study . The investigate whether treatment low-dose glibenclamide lead decrease fast glucagon level patient type 2 diabetes , whether impact overall blood glucose control . It conduct Clinical Research Unit ( CRU ) Oxford Centre Diabetes , Endocrinology Metabolism ( OCDEM ) Churchill Hospital , Oxford . The aim find dose glibenclamide cause reduction fast glucagon level patient T2DM . Participants self-administer increase dos oral glibenclamide suspension 0.3-6mg every 3 4 day , period 21 day . They attend CRU fast pre-dose blood test insulin , glucagon , C- peptide glucose prior dose change . Additionally , participant option continuous glucose monitoring ( CGM ) sensor attach duration study , check change visit CRU . This measure impact treatment overall blood glucose control . No human trial use dos glibenclamide 5mg previously measurement insulin glucagon secretion . Our sample size calculation base experimental data isolate human islet T2DM donor , perform Professor Patrik Rorsman 's lab . These suggest 15 participant ( allow 15 % dropout ) would give study 80 % power detect 57 % reduction baseline glucagon level alpha error 5 % . Details study visit follow : CRU visit 1 ( 1 hour ) : 1 . Informed consent obtain member clinical trial team . 2 . Inclusion exclusion criterion check . 3 . Concomitant medication check . 4 . Demographics document case report form ( CRF ) : date birth , gender , weight , height . 5 . Observations document CRF : rest heart rate blood pressure . 6 . Blood sample HbA1c safety blood test ( full blood count , renal function test , electrolytes liver function test ) . 7 . Pregnancy test woman childbearing age ( 18-49 year old ) . 8 . Participant inform fast next CRU visit . CRU visit 2 ( 1 hour ) : 1 . Observations document CRF : rest heart rate blood pressure 2 . Fasting blood sample insulin , glucagon , C-peptide glucose . 3 . CGM sensor insert . 4 . Participants issue oral glibenclamide suspension ( 0.6mg/ml ) dosing syringe . Educated self-administration give dose schedule . CRU visit 3 ( 30 minute ) : 1 . Observations document CRF : rest heart rate blood pressure 2 . Fasting blood sample insulin , glucagon , C-peptide glucose . 3 . CGM sensor change data download . CRU visit 4 - 8 ( 30 minute ) : 1 . Observations document CRF : rest heart rate blood pressure 2 . Fasting pre-dose blood sample insulin , glucagon , C-peptide glucose . 3 . CGM sensor change data download . 4 . Adverse event record . 5 . Check compliance . ( visit 7 : Participants issue 6mg/ml oral glibenclamide suspension ) CRU visit 9 ( 30 minute ) : 1 . Observations document CRF : rest heart rate blood pressure 2 . Fasting pre-dose blood sample insulin , glucagon , C-peptide glucose . 3 . CGM sensor remove data download . CGM system return CRU . 4 . Adverse event record . 5 . Check compliance . 6 . Unused oral glibenclamide suspension return &amp; document drug accountability . 7 . Participants informed end study . Telephone follow-up ( 15min ) : Documentation adverse event occur follow discontinuation trial medication . Home visit : For participant use CGM unable attend CRU fast blood test , early morning home visit arrange . These conducted member research team replace CRU visit 3-9 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Diagnosis T2DM . Age 18 year . Diet control metformin diabetic control . Body mass index 40 kg/m2 less . HbA1c 6.0 % 9.5 % ( 42mmol/mol 80mmol/mol ) inclusive . Taking antidiabetic therapy metformin Pregnancy woman childbearing age without adequate contraception Women breastfeed Major psychiatric disease include diagnose eat disorder , history drug alcohol abuse Known sightthreatening retinopathy Renal impairment ( eGFR &lt; 60 ml/min ; CKD Stage 3 ) Abnormal liver function test ( &gt; 1.5 x upper limit normal range ) Known ischaemic heart disease heart failure Known history stroke Known history porphyria Concomitant use miconazole oral antifungal medication . Known suspect allergy trial product relate product Oral steroid treatment 30 day prior start time trial period . Known malignancy condition circumstance , opinion investigator , would affect patient 's ability participate protocol . Ketoacidosis Felt unsuitable participate trial opinion Chief Investigator . Receipt investigational trial drug within 3 month prior participation current trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>glibenclamide</keyword>
	<keyword>glucagon</keyword>
</DOC>